1.22

7.96% 0.09

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.22, with a volume of 1.93M. It is up +7.96% in the last 24 hours and down -13.48% over the past month. Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Previous Close:

$1.13

Open:

$1.14

24h Volume:

1.93M

Relative Volume:

1.76

Market Cap:

$86.26M

Revenue:

Net Income/Loss:

$-95.71M

P/E Ratio:

-0.5101

EPS:

-2.3915

Net Cash Flow:

$-87.27M

1W Performance:

+4.27%

1M Performance:

-13.48%

6M Performance:

-40.49%

1Y Performance:

-54.65%

1-Day Range:

$1.14

$1.265

1-Week Range:

$1.07

$1.265

52-Week Range:

$0.8719

$3.08

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.22	79.90M	0	-95.71M	-87.27M	-2.3915
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Mar 25, 2026

Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2026

Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo

Mar 25, 2026

Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey

Mar 25, 2026

Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Mar 25, 2026

Biomea Fusion 2025 Financial Report - AlphaStreet

Mar 25, 2026

Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart

Mar 24, 2026

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget

Mar 24, 2026

Biomea Fusion (NASDAQ:BMEA) Issues Quarterly Earnings Results - MarketBeat

Mar 24, 2026

Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView

Mar 24, 2026

BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView

Mar 24, 2026

Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan

Mar 24, 2026

Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 24, 2026

Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan

Mar 24, 2026

Biomea lines up four diabetes and obesity readouts before cash runs out - Stock Titan

Mar 24, 2026

Mar 23, 2026

Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union

Mar 23, 2026

Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan

Mar 22, 2026

Mar 21, 2026

BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 21, 2026

Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn

Mar 21, 2026

Mar 18, 2026

Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat

Mar 18, 2026

Mar 16, 2026

Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView

Mar 16, 2026